NASDAQ:TTOO T2 Biosystems (TTOO) Stock Forecast, Price & News $0.07 -0.01 (-12.41%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$0.06▼$0.0950-Day Range$0.07▼$0.4652-Week Range$0.06▼$15.00Volume87.02 million shsAverage Volume41.99 million shsMarket Capitalization$1.76 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media T2 Biosystems MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside3,441.1% Upside$2.50 Price TargetShort InterestHealthy2.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.60Based on 6 Articles This WeekInsider TradingSelling Shares$115 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 stars 3.0 Analyst's Opinion Consensus RatingT2 Biosystems has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, T2 Biosystems has a forecasted upside of 3,441.1% from its current price of $0.07.Amount of Analyst CoverageT2 Biosystems has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.04% of the float of T2 Biosystems has been sold short.Short Interest Ratio / Days to CoverT2 Biosystems has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in T2 Biosystems has recently decreased by 4.91%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldT2 Biosystems does not currently pay a dividend.Dividend GrowthT2 Biosystems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TTOO. Previous Next 3.1 News and Social Media Coverage News SentimentT2 Biosystems has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for T2 Biosystems this week, compared to 2 articles on an average week.Search Interest32 people have searched for TTOO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows10 people have added T2 Biosystems to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, T2 Biosystems insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $115.00 in company stock.Percentage Held by InsidersOnly 3.27% of the stock of T2 Biosystems is held by insiders. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here About T2 Biosystems (NASDAQ:TTOO) StockT2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.Read More Receive TTOO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter. Email Address TTOO Stock News HeadlinesJune 10, 2023 | americanbankingnews.comT2 Biosystems (NASDAQ:TTOO) Now Covered by StockNews.comJune 9, 2023 | finance.yahoo.comT2 Biosystems Announces Clinical Collaboration with Vanderbilt University Medical Center to Implement and Evaluate the T2Bacteria Panel for Clinical UseJune 10, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.June 6, 2023 | investorplace.comWhy Is T2 Biosystems (TTOO) Stock Up 17% Today?June 5, 2023 | msn.comT2 Biosystems seeks FDA breakthrough designation for C. auris testJune 5, 2023 | finance.yahoo.comT2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic TestJune 2, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on T2 Biosystems (NASDAQ:TTOO)June 1, 2023 | investorplace.comWhy Is T2 Biosystems (TTOO) Stock Up 29% Today?June 10, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 30, 2023 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company HistoryMay 30, 2023 | msn.comT2 Biosystems up 31%, gets second largest order for sepsis-driven instrumentMay 30, 2023 | finance.yahoo.comT2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company HistoryMay 26, 2023 | seekingalpha.comTTOO T2 Biosystems, Inc.May 25, 2023 | americanbankingnews.comT2 Biosystems (NASDAQ:TTOO) Coverage Initiated at StockNews.comMay 24, 2023 | bizjournals.comDiagnostics maker T2 Biosystems lays off 40May 24, 2023 | markets.businessinsider.comT2 Biosystems (TTOO) Receives a Hold from BTIGMay 24, 2023 | finance.yahoo.comQ1 2023 T2 Biosystems Inc Earnings CallMay 23, 2023 | markets.businessinsider.comT2 Biosystems earnings preview: what Wall Street is expectingMay 23, 2023 | markets.businessinsider.comT2 Biosystems To Explore All Potential Strategic AlternativesMay 23, 2023 | msn.comT2 Biosystems files for FDA approval of T2Biothreat panelMay 23, 2023 | benzinga.comT2 Biosystems Stock Tumbles: Company Lays Off 30% Of Workforce, Clocks 70% Decline In Q1 RevenuesMay 23, 2023 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Announces First Quarter 2023 Financial ResultsMay 23, 2023 | finance.yahoo.comT2 Biosystems Announces First Quarter 2023 Financial ResultsMay 22, 2023 | finance.yahoo.comT2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 23, 2023May 19, 2023 | msn.comT2 Biosystems's Earnings: A PreviewMay 17, 2023 | finance.yahoo.comT2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 22, 2023May 15, 2023 | finance.yahoo.comT2 Biosystems Postpones Reporting of First Quarter 2023 Financial ResultsSee More Headlines TTOO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TTOO Company Calendar Last Earnings11/04/2021Today6/10/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTOO CUSIPN/A CIK1492674 Webwww.t2biosystems.com Phone(781) 761-4646Fax781-357-3080Employees158Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.50 High Stock Price Forecast$2.50 Low Stock Price Forecast$2.50 Forecasted Upside/Downside+3,441.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,000,000.00 Net Margins-370.13% Pretax Margin-370.13% Return on EquityN/A Return on Assets-163.06% Debt Debt-to-Equity RatioN/A Current Ratio1.06 Quick Ratio0.78 Sales & Book Value Annual Sales$22.31 million Price / Sales0.08 Cash FlowN/A Price / Cash FlowN/A Book Value($5.14) per share Price / Book-0.01Miscellaneous Outstanding Shares24,890,000Free Float24,074,000Market Cap$1.76 million OptionableOptionable Beta0.35 Key ExecutivesMr. John J. Sperzel III (Age 60)B.Sc., Pres, CEO & Chairman Comp: $865.5kMr. John M. Sprague CPA (Age 65)Chief Financial Officer Comp: $482.33kMr. Michael Terrence Gibbs Esq. (Age 52)Sr. VP & Gen. Counsel Comp: $487.33kMs. Kelley J. Morgan (Age 47)Chief People Officer Dr. Aparna Jha Ahuja M.D. (Age 56)Chief Medical Officer & Chairman of Scientific Advisory Board Mr. Brett A. Giffin (Age 64)Chief Commercial Officer Dr. Roger Smith Ph.D. (Age 58)Sr. VP of Science R&D More ExecutivesKey CompetitorsQuoin PharmaceuticalsNASDAQ:QNRXAssureNASDAQ:IONMINVO BioscienceNASDAQ:INVOG Medical InnovationsNASDAQ:GMVDMotus GINASDAQ:MOTSView All CompetitorsInsiders & InstitutionsAnson Funds Management LPBought 525,038 shares on 5/19/2023Ownership: 2.590%Sabby Management LLCBought 749,599 shares on 5/16/2023Ownership: 3.697%Hudson Bay Capital Management LPBought 651,300 shares on 5/16/2023Ownership: 3.212%CVI Holdings LLCBought 549,542 shares on 5/16/2023Ownership: 2.710%Anson Funds Management LPBought 525,038 shares on 5/15/2023Ownership: 2.590%View All Insider TransactionsView All Institutional Transactions TTOO Stock - Frequently Asked Questions Should I buy or sell T2 Biosystems stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TTOO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTOO, but not buy additional shares or sell existing shares. View TTOO analyst ratings or view top-rated stocks. What is T2 Biosystems' stock price forecast for 2023? 4 equities research analysts have issued 12 month price objectives for T2 Biosystems' stock. Their TTOO share price forecasts range from $2.50 to $2.50. On average, they expect the company's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 3,441.1% from the stock's current price. View analysts price targets for TTOO or view top-rated stocks among Wall Street analysts. How have TTOO shares performed in 2023? T2 Biosystems' stock was trading at $1.42 at the start of the year. Since then, TTOO stock has decreased by 95.0% and is now trading at $0.0706. View the best growth stocks for 2023 here. When is T2 Biosystems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our TTOO earnings forecast. How were T2 Biosystems' earnings last quarter? T2 Biosystems, Inc. (NASDAQ:TTOO) posted its quarterly earnings data on Thursday, November, 4th. The medical equipment provider reported ($4.00) earnings per share for the quarter, hitting analysts' consensus estimates of ($4.00). The medical equipment provider earned $7.43 million during the quarter. During the same quarter in the prior year, the firm earned ($4.00) EPS. When did T2 Biosystems' stock split? T2 Biosystems's stock reverse split before market open on Thursday, October 13th 2022. The 1-50 reverse split was announced on Thursday, October 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What is John McDonough's approval rating as T2 Biosystems' CEO? 36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of T2 Biosystems own? Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT). What is T2 Biosystems' stock symbol? T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO." Who are T2 Biosystems' major shareholders? T2 Biosystems' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sabby Management LLC (3.70%), Hudson Bay Capital Management LP (3.21%), CVI Holdings LLC (2.71%), Anson Funds Management LP (2.59%), Anson Funds Management LP (2.59%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Adrian M Jones, Alec Barclay, Brett A Giffin, Goldman Sachs & Co Llc, John J Sperzel III, John M Sprague, John Mcdonough and Michael Terrence Gibbs. View institutional ownership trends. How do I buy shares of T2 Biosystems? Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is T2 Biosystems' stock price today? One share of TTOO stock can currently be purchased for approximately $0.07. How much money does T2 Biosystems make? T2 Biosystems (NASDAQ:TTOO) has a market capitalization of $1.76 million and generates $22.31 million in revenue each year. How many employees does T2 Biosystems have? The company employs 158 workers across the globe. How can I contact T2 Biosystems? T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The official website for the company is www.t2biosystems.com. The medical equipment provider can be reached via phone at (781) 761-4646, via email at ir@t2biosystems.com, or via fax at 781-357-3080. This page (NASDAQ:TTOO) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding T2 Biosystems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.